FDA Hits Reset Button; Approves Everything

(Press Release embargoed until April 1) – ooops! Sorry…. In response to the endless backlog of work, and the constant carping of all of its constituents, FDA Chief Dr. “Big Maggie” Cheeseburg decided that the best way to clear things up was to do one massive, sweeping approval of everything on the docket and just [...]

Read Full Post »

Impactiviti Daily 033110

I realized yesterday that for those who subscribe to the Impactiviti blog via e-mail, the delivery wasn’t occurring until that day after. A friend showed me how to fix that setting in Feedburner – so the Impactiviti Daily News should be arriving hot and fresh with your morning coffee. If you’re not already subscribed via [...]

Read Full Post »

Impactiviti Daily 033010

***** TODAY’S NEWS Patenting genes called into question. Frankly, this is a legal/medical/sociological discussion that needs to happen. Cephalon‘s jet lag indication on Nuvigil may be stuck on the runway for a while. When companies – and agencies – can’t count. An expensively amusing tale. The Top 20 Drugmakers, listed. Another experimental cancer drug hits [...]

Read Full Post »

Impactiviti Daily 032910

***** TODAY’S NEWS Antisoma/Novartis experimental drug hits the proverbial wall on Phase III lung cancer trial. Study halted. New test may predict which MS patients will most benefit from beta interferons. This is actually a big deal – Researchers at Stanford University analyzed mice with an induced disorder similar to MS and blood samples saved [...]

Read Full Post »

Impactiviti Daily 032610

***** TODAY’S NEWS Little Pricey Pill: A BusinessWeek slam on the Nexium approach to me-too drug marketing. Pfizer and the Neurontin marketing fraud: $142M please. Head-to-head MS drug effectiveness studies coming. This should be interesting. RECOMMENDED Video storytelling – Impactiviti’s vendor/partners have just what you need for directing and producing corporate videos.  Contact us (stevew [...]

Read Full Post »

But Are We Communicating?

As someone deeply immersed in pharma communications, and especially the newer realm of social networking, I’ve been closely following the ongoing process of the industry/FDA dance, trying to figure out how social media/web 2.0 approaches “fit” with pharmaceutical manufacturers and their various audiences. And I keep wondering if we’re going about the whole thing the [...]

Read Full Post »

Impactiviti Daily 032510

***** TODAY’S NEWS What about those bone fracture risks with biophosphonate drugs? The jury is still out – A new study gives reassuring news about the safety of Fosamax and Reclast, bone-building drugs taken by millions of American women. It found that long-term use does not significantly raise the risk of a rare type of [...]

Read Full Post »

Impactiviti Daily 032310

***** TODAY’S NEWS Boehringer‘s Mirapex ER for once-daily Parkinson’s treatment is approved by FDA. When the FDA surprisingly approves a previously-rejected drug. Don’t do this. Can you tell it was a somewhat sparse day for news? Yeah – some days are like that… RECOMMENDED Marketing Training – Public courses for your brand managers (all levels), [...]

Read Full Post »

Impactiviti Daily 032210

***** TODAY’S NEWS Drugmakers, profits, and penalties – “There’s an unwritten business plan,” he says. “They’re drivers that knowingly speed. If stopped, they pay the fine, and then they do it again.” more Pharma industry dodges threats in new healthcare bill. A summary of some of the commentary (with links) submitted to the FDA about [...]

Read Full Post »

Impactiviti Daily 031810

***** TODAY’S NEWS It appears that the 3-way bidding war for Ratiopharm is going to be won by Teva. So, who will Pfizer go after next? Abraxis jumps after successful lung cancer comparative trial – The Abraxis product, Abraxane, combines paclitaxel with a human protein to administer it in higher doses, according to company data. [...]

Read Full Post »